Literature DB >> 16025000

Synergistic endocrine induction by GLP-1 and TGF-beta in the developing pancreas.

Eri Tei1, Sheilendra Mehta, Sidhartha S Tulachan, Hooi Yew, Mark Hembree, Barry Preuett, Charles L Snyder, Atsuyuki Yamataka, Takeshi Miyano, George K Gittes.   

Abstract

OBJECTIVES: Glucagon-like peptide-1 (GLP-1) is known to stimulate glucose-dependent insulin production and secretion by pancreatic beta-cells. Preliminary evidence suggests that GLP-1 may also influence endocrine differentiation from pancreatic progenitor cells. Additionally, TGF-beta signaling can also control endocrine differentiation by both inhibiting proliferation and enhancing differentiation of endocrine progenitor cells to become mature beta-cells. Here we document synergy of these two signaling pathways in the differentiation of endocrine cells in the developing pancreas.
METHODS: Embryonic pancreas was harvested from mice at day 11.5 and cultured for six days with GLP-1 agonist, exendin-4, and/or TGF-beta1 ligand. Also, a pan-neutralizing TGF-beta isoform antibody was used alone or with exendin-4 to study TGF-beta inhibition in this system. Pancreatic cultures were processed for immunohistochemistry.
RESULTS: Exogenous TGF-beta1 and exendin-4 each individually enhanced both insulin and glucagon differentiation dose-dependently. However, when combined there was an additive effect to a 4.5-fold increase in insulin-positive differentiation. We also saw suppression of amylase-positive differentiation. Surprisingly, TGF-beta pan-neutralizing antibody also gave an augmentation of endocrine differentiation by 1.5 to 2-fold, but no synergistic effect was seen with exendin-4.
CONCLUSION: We conclude that TGF-beta isoforms have a specific synergistic role with GLP-1 pathway signaling in early pancreatic development, toward endocrine differentiation and away from acinar differentiation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16025000     DOI: 10.1097/01.mpa.0000172566.70619.58

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  6 in total

Review 1.  Mechanisms of action of glucagon-like peptide 1 in the pancreas.

Authors:  Máire E Doyle; Josephine M Egan
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

Review 2.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

Review 3.  Human pluripotent stem cells: an emerging model in developmental biology.

Authors:  Zengrong Zhu; Danwei Huangfu
Journal:  Development       Date:  2013-02       Impact factor: 6.868

Review 4.  Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass.

Authors:  Bernard Portha; Cécile Tourrel-Cuzin; Jamileh Movassat
Journal:  Exp Diabetes Res       Date:  2011-05-22

5.  Therapeutic efficacy of differentiated versus undifferentiated mesenchymal stem cells in experimental type I diabetes in rat.

Authors:  M A Wassef; H Fouad; D Sabry; N Afifi; A M Abbas; W Mostafa; S H Ahmed
Journal:  Biochem Biophys Rep       Date:  2016-02-09

6.  Methylation status of vault RNA 2-1 promoter is a predictor of glycemic response to glucagon-like peptide-1 analog therapy in type 2 diabetes mellitus.

Authors:  Chia-Hung Lin; Yun-Shien Lee; Yu-Yao Huang; Chi-Neu Tsai
Journal:  BMJ Open Diabetes Res Care       Date:  2021-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.